These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

786 related items for PubMed ID: 15735703

  • 1. Survivin mediates resistance to antiandrogen therapy in prostate cancer.
    Zhang M, Latham DE, Delaney MA, Chakravarti A.
    Oncogene; 2005 Apr 07; 24(15):2474-82. PubMed ID: 15735703
    [Abstract] [Full Text] [Related]

  • 2. Adenovirus-mediated inhibition of survivin expression sensitizes human prostate cancer cells to paclitaxel in vitro and in vivo.
    Zhang M, Mukherjee N, Bermudez RS, Latham DE, Delaney MA, Zietman AL, Shipley WU, Chakravarti A.
    Prostate; 2005 Aug 01; 64(3):293-302. PubMed ID: 15754318
    [Abstract] [Full Text] [Related]

  • 3. Ribozyme-mediated inhibition of survivin expression increases spontaneous and drug-induced apoptosis and decreases the tumorigenic potential of human prostate cancer cells.
    Pennati M, Binda M, Colella G, Zoppe' M, Folini M, Vignati S, Valentini A, Citti L, De Cesare M, Pratesi G, Giacca M, Daidone MG, Zaffaroni N.
    Oncogene; 2004 Jan 15; 23(2):386-94. PubMed ID: 14724567
    [Abstract] [Full Text] [Related]

  • 4. Androgen sensitivity related proteins in hormone-sensitive and hormone-insensitive prostate cancer cell lines treated by androgen antagonist bicalutamide.
    Madarová J, Lukesová M, Hlobilková A, Riháková P, Murray PG, Student V, Vojtsek B, Kolár Z.
    Neoplasma; 2001 Jan 15; 48(5):419-24. PubMed ID: 11845989
    [Abstract] [Full Text] [Related]

  • 5. Activation of mitogen-activated protein kinase pathway by the antiandrogen hydroxyflutamide in androgen receptor-negative prostate cancer cells.
    Lee YF, Lin WJ, Huang J, Messing EM, Chan FL, Wilding G, Chang C.
    Cancer Res; 2002 Nov 01; 62(21):6039-44. PubMed ID: 12414626
    [Abstract] [Full Text] [Related]

  • 6. 5alpha-androstane-3alpha,17beta-diol supports human prostate cancer cell survival and proliferation through androgen receptor-independent signaling pathways: implication of androgen-independent prostate cancer progression.
    Yang Q, Titus MA, Fung KM, Lin HK.
    J Cell Biochem; 2008 Aug 01; 104(5):1612-24. PubMed ID: 18320593
    [Abstract] [Full Text] [Related]

  • 7. Antiandrogen-like actions of an antioxidant on survivin, Bcl-2 and PSA in human prostate cancer cells.
    Gunawardena K, Campbell LD, Meikle AW.
    Cancer Detect Prev; 2005 Aug 01; 29(4):389-95. PubMed ID: 16139439
    [Abstract] [Full Text] [Related]

  • 8. Longitudinal analysis of androgen deprivation of prostate cancer cells identifies pathways to androgen independence.
    D'Antonio JM, Ma C, Monzon FA, Pflug BR.
    Prostate; 2008 May 15; 68(7):698-714. PubMed ID: 18302219
    [Abstract] [Full Text] [Related]

  • 9. Change of the cell cycle after flutamide treatment in prostate cancer cells and its molecular mechanism.
    Wang Y, Shao C, Shi CH, Zhang L, Yue HH, Wang PF, Yang B, Zhang YT, Liu F, Qin WJ, Wang H, Shao GX.
    Asian J Androl; 2005 Dec 15; 7(4):375-80. PubMed ID: 16281084
    [Abstract] [Full Text] [Related]

  • 10. Prostate cancer cells increase androgen sensitivity by increase in nuclear androgen receptor and androgen receptor coactivators; a possible mechanism of hormone-resistance of prostate cancer cells.
    Fujimoto N, Miyamoto H, Mizokami A, Harada S, Nomura M, Ueta Y, Sasaguri T, Matsumoto T.
    Cancer Invest; 2007 Feb 15; 25(1):32-7. PubMed ID: 17364555
    [Abstract] [Full Text] [Related]

  • 11. Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells.
    Tso CL, McBride WH, Sun J, Patel B, Tsui KH, Paik SH, Gitlitz B, Caliliw R, van Ophoven A, Wu L, deKernion J, Belldegrun A.
    Cancer J; 2000 Feb 15; 6(4):220-33. PubMed ID: 11038142
    [Abstract] [Full Text] [Related]

  • 12. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
    Suzuki H, Okihara K, Miyake H, Fujisawa M, Miyoshi S, Matsumoto T, Fujii M, Takihana Y, Usui T, Matsuda T, Ozono S, Kumon H, Ichikawa T, Miki T, Nonsteroidal Antiandrogen Sequential Alternation for Prostate Cancer Study Group.
    J Urol; 2008 Sep 15; 180(3):921-7. PubMed ID: 18635218
    [Abstract] [Full Text] [Related]

  • 13. Pharmacological targeting of constitutively active truncated androgen receptor by nigericin and suppression of hormone-refractory prostate cancer cell growth.
    Mashima T, Okabe S, Seimiya H.
    Mol Pharmacol; 2010 Nov 15; 78(5):846-54. PubMed ID: 20709811
    [Abstract] [Full Text] [Related]

  • 14. Expression of clusterin, XIAP and survivin, and their changes by camptothecin (CPT) treatment in CPT-resistant PC-3 and CPT-sensitive LNCaP cells.
    Mizutani K, Matsumoto K, Hasegawa N, Deguchi T, Nozawa Y.
    Exp Oncol; 2006 Sep 15; 28(3):209-15. PubMed ID: 17080014
    [Abstract] [Full Text] [Related]

  • 15. Functional characterization of mutant androgen receptors from androgen-independent prostate cancer.
    Fenton MA, Shuster TD, Fertig AM, Taplin ME, Kolvenbag G, Bubley GJ, Balk SP.
    Clin Cancer Res; 1997 Aug 15; 3(8):1383-8. PubMed ID: 9815822
    [Abstract] [Full Text] [Related]

  • 16. Gene expression profiling revealed survivin as a target of 3,3'-diindolylmethane-induced cell growth inhibition and apoptosis in breast cancer cells.
    Rahman KW, Li Y, Wang Z, Sarkar SH, Sarkar FH.
    Cancer Res; 2006 May 01; 66(9):4952-60. PubMed ID: 16651453
    [Abstract] [Full Text] [Related]

  • 17. Identification of mu-crystallin as an androgen-regulated gene in human prostate cancer.
    Malinowska K, Cavarretta IT, Susani M, Wrulich OA, Uberall F, Kenner L, Culig Z.
    Prostate; 2009 Jul 01; 69(10):1109-18. PubMed ID: 19353593
    [Abstract] [Full Text] [Related]

  • 18. TGF-beta signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells.
    Zhu ML, Partin JV, Bruckheimer EM, Strup SE, Kyprianou N.
    Prostate; 2008 Feb 15; 68(3):287-95. PubMed ID: 18163430
    [Abstract] [Full Text] [Related]

  • 19. Transforming growth factor beta induces apoptosis through repressing the phosphoinositide 3-kinase/AKT/survivin pathway in colon cancer cells.
    Wang J, Yang L, Yang J, Kuropatwinski K, Wang W, Liu XQ, Hauser J, Brattain MG.
    Cancer Res; 2008 May 01; 68(9):3152-60. PubMed ID: 18451140
    [Abstract] [Full Text] [Related]

  • 20. Hydroxyflutamide enhances cellular sensitivity to 5-fluorouracil by suppressing thymidylate synthase expression in bicalutamide-resistant human prostate cancer cells.
    Kawabata R, Oie S, Oka T, Takahashi M, Kanayama H, Itoh K.
    Int J Oncol; 2011 Mar 01; 38(3):665-76. PubMed ID: 21243325
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.